Skip to main content
Quoin Pharmaceuticals, Ltd. logo

Quoin Pharmaceuticals, Ltd. — Investor Relations & Filings

Ticker · QNRX ISIN · US74907L1026 US Manufacturing
Open in API
Filings indexed 542 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country US United States of America
Listing US QNRX

About Quoin Pharmaceuticals, Ltd.

https://quoinpharma.com/

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare and orphan diseases. The company's lead product candidate, QRX003, is in development for the treatment of Netherton Syndrome, a rare hereditary skin disorder. Quoin utilizes the proprietary Invisicare delivery technology, for which it holds exclusive rights for orphan rare skin disease applications. The company's strategy involves establishing exclusive international marketing and distribution partnerships to augment its own commercial infrastructure in the US, Europe, and Japan, ensuring its products reach patients globally.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 10% confidence The document is a Form 8-K current report filed with the SEC reporting Regulation FD disclosure and other events. It is a general regulatory announcement rather than a full financial report or other specialized filing. This falls under the Regulatory Filings category (RNS).
2026-06-04 English
424B3
Regulatory Filings Classification · 91% confidence The document is a Prospectus Supplement No. 1 filed under SEC Rule 424(b)(3) updating the selling shareholder table in a registration prospectus. It is not an annual or interim financial report, nor a management discussion or investor presentation. It is a regulatory filing amending a previously filed prospectus. It does not fit any of the more specific categories such as share issue announcements (SHA) or capital updates (CAP), so it falls under the fallback category Regulatory Filings (RNS).
2026-06-02 English
10-Q - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
10-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
Annual Report FY 2025
2026-03-26 English
8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2026, for Quoin Pharmaceuticals Ltd. It announces the company's fourth quarter and fiscal year 2025 financial results and includes a press release as an exhibit. The text explicitly states that the financial results are announced via a press release attached as Exhibit 99.1, and the document itself is a current report (Form 8-K) rather than the full financial report. The document length is 4380 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements of financial results in a Form 8-K with an attached press release are classified as Earnings Release (ER).
2026-03-26 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.